ADC / XDC

Delve into the world of ADC / XDC in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on ADC / XDC to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

BeOne Medicines Reports Q3 2026 Global Revenues of USD 1.9 Billion, Up 34 % – BRUKINSA Tops USD 1.4 Billion as GAAP Net Income Reaches USD 385 Million
Company

BeOne Medicines Reports Q3 2026 Global Revenues of USD 1.9 Billion, Up 34 % – BRUKINSA Tops USD 1.4 Billion as GAAP Net Income Reaches USD 385 Million

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results for the third quarter of 2026, reporting global revenues of USD 1.9 billion, a 34 % year‑on‑year…

GenSci's Inhaled siRNA GenSci117 Targeting MMP7 Clears NMPA Registration Clinical Trial Acceptance – A Class 1 RNAi Candidate for Idiopathic Pulmonary Fibrosis

GenSci’s Inhaled siRNA GenSci117 Targeting MMP7 Clears NMPA Registration Clinical Trial Acceptance – A Class 1 RNAi Candidate for Idiopathic Pulmonary Fibrosis

Qyuns Therapeutics Out‑Licenses TL1A × IL‑17 Bispecific Program to Caldera Therapeutics – USD 30 Million Upfront with Up to USD 750 Million in Milestones

Qyuns Therapeutics Out‑Licenses TL1A × IL‑17 Bispecific Program to Caldera Therapeutics – USD 30 Million Upfront with Up to USD 750 Million in Milestones

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
AstraZeneca and Daiichi Sankyo Submit Priority‑Review sBLA for Enhertu as First‑Line Therapy for HER2‑Positive Breast Cancer
CompanyDrug

AstraZeneca and Daiichi Sankyo Submit Priority‑Review sBLA for Enhertu as First‑Line Therapy for HER2‑Positive Breast Cancer

FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer
CompanyDrug

FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer

DualityBio Initiates Global Phase Ia/Ib Study of ADAM9‑Targeting ADC DB‑1317
Drug

DualityBio Initiates Global Phase Ia/Ib Study of ADAM9‑Targeting ADC DB‑1317

Hengrui Pharma & Glenmark Partner on Trastuzumab Rezecan ADC for HER2‑Positive Lung Cancer
CompanyDeals

Hengrui Pharma & Glenmark Partner on Trastuzumab Rezecan ADC for HER2‑Positive Lung Cancer

Huadong Medicine Secures FDA IND Approval for HDM2017 ADC
CompanyDrug

Huadong Medicine Secures FDA IND Approval for HDM2017 ADC

China’s Insilico, Mabwell, and Chemexpress Forge AI‑Driven ADC Collaboration
CompanyDeals

China’s Insilico, Mabwell, and Chemexpress Forge AI‑Driven ADC Collaboration

Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
CompanyDrug

Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer

Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson & Johnson and Roche
CompanyDeals

Shanghai Henlius Biotech Negotiates Potential Sale of HLX43 ADC to Johnson & Johnson and Roche

Show More